Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Curtis Jantzi

Family Medicine Kingsport, TN Doctor of Osteopathy

NPI 1740372267 CMS profile 953915

2033 Meadowview Ln, Ste 200, Kingsport, TN 37660

Open in the dashboard

General payments

$39,407

705 records reported · program years 2019–2025

Research payments

$1,805

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,265,430 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Curtis Jantzi of Kingsport, TN is reported in the CMS Open Payments database as having received $39,407 across 705 general payments and $1,805 in research payments paid to them. Separately, studies naming them as principal investigator received $1,265,430 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,313 93
2024 General $7,844 107
2023 General $15,539 94
2022 General $5,674 91
2022 Research $1,805 6
2021 General $3,876 166
2020 General $3,229 82
2019 General $1,933 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Curtis Jantzi
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Curtis Jantzi were reported at $1,313. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Curtis Jantzi Family Medicine median Middle half National median
2019 $1,933 $150 $41–$543 $163
2020 $3,229 $120 $32–$415 $114
2021 $3,876 $137 $35–$551 $132
2022 $5,674 $137 $37–$512 $149
2023 $15,539 $149 $42–$545 $160
2024 $7,844 $156 $44–$560 $164
2025 $1,313 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $19,733 149 payments
  2. Sanofi-Aventis U.S. LLC $9,209 47 payments
  3. AstraZeneca Pharmaceuticals LP $2,265 31 payments
  4. AbbVie, Inc. $1,481 148 payments
  5. Novo Nordisk AS $1,163 4 payments
  6. Janssen Research & Development, LLC $1,143 8 payments
  7. GlaxoSmithKline, LLC. $891 88 payments
  8. Astellas Pharma US Inc $510 29 payments
  9. Pfizer Inc. $407 26 payments
  10. Esperion Therapeutics, Inc. $248 14 payments
  11. Other $2,357 161 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $20,152 7 payments
  2. Food and Beverage $10,444 673 payments
  3. Travel and Lodging $8,754 23 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $45 1 payment
  5. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. SOLIQUA 100/33 Endocrine & Metabolic Diseases $6,783 28 payments
  2. SOLIQUA 100/33 Endocrinology $2,282 6 payments
  3. Ozempic $876 90 payments
  4. TRELEGY ELLIPTA $825 76 payments
  5. RYBELSUS $739 77 payments
  6. VRAYLAR $717 66 payments
  7. UBRELVY $480 41 payments
  8. MYRBETRIQ $369 21 payments
  9. QULIPTA $337 29 payments
  10. FARXIGA $334 7 payments
  11. Other $5,560 395 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novo Nordisk AS $1,805 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 200 drugs

Part D claims

19,030

Median for Family Practice: 1,826

Drug cost

$1,536,049

Median for Family Practice: $120,094

Branded share of claims

20.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 166 $191,360
Eliquis Apixaban Brand 193 $167,088
Mounjaro Tirzepatide Brand 86 $101,921
Trulicity Dulaglutide Brand 67 $93,697
Xarelto Rivaroxaban Brand 77 $88,219
Tresiba Flextouch U-200 Insulin Degludec Brand 57 $80,988
Farxiga Dapagliflozin Propanediol Brand 70 $76,105
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 71 $69,989
Jardiance Empagliflozin Brand 54 $64,662
Xifaxan Rifaximin Brand 11 $35,901

The 10 drugs with the highest cost, of 200 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$115,853

Of which drugs: $10,890

Medicare patients

283

Average age 72

Services billed

2,498

119 women, 164 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 38%
Chronic kidney disease 33%
Depression 29%
Ischemic heart disease 26%
Atrial fibrillation 19%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 66 69 $5,586
Pcv20 vaccine im 90677 Office 17 17 $4,956

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $161
$161 — —
UBRELVY
  • AbbVie, Inc. $98
$98 — —
NURTEC ODT
  • PFIZER INC. $75
$75 — —
AREXVY
  • GlaxoSmithKline, LLC. $66
$66 — —
ZAVZPRET
  • PFIZER INC. $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

711 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record